Russia's R-Pharm links with Rosatom on production

17 September 2018

Russian nuclear monopoly firm Rosatom Healthcare has joined forces with one of the country’s leading drugmakers R-Pharm, to invest 10 billion roubles ($147 million) in the establishment of joint production of drugs in Moscow this year, according to the companies.

An official spokesman of Rosatom, a pharmaceutical arm of the company, said the sides are planning to launch a wide range of drugs, some of which will be innovative and will have no analogues in the world, reports The Pharma Letter’s local correspondent.

According to head of R-Pharm Alexey Repik, to date, the companies have already completed the design of the enterprise and are ready to start construction works.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK